Canada's Aurora Cannabis Q3 revenue beats on higher sales in Germany and Poland

Overview

• Canada medical cannabis firm's fiscal Q3 revenue rose, beating analyst expectations

• Adjusted EBITDA for fiscal Q3 remained strong

• Company to exit lower-margin consumer cannabis markets, focusing on medical cannabis

Outlook

• Aurora expects fiscal 2026 global medical cannabis revenue between C$269 mln and C$281 mln

• Company anticipates fiscal 2026 adjusted EBITDA to rise to C$52 mln-C$57 mln

• Aurora plans to exit certain Canadian consumer cannabis markets in Q4 FY26

Result Drivers

• MEDICAL CANNABIS GROWTH - Aurora's global medical cannabis net revenue increased by 12%, driven by higher sales in Germany and Poland

• CONSUMER CANNABIS DECLINE - Consumer cannabis net revenue fell 48% as Aurora prioritized higher-margin medical cannabis products

• PLANT PROPAGATION INCREASE - Plant propagation net revenue rose 27% due to organic growth and expanded product offerings

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Aurora Cannabis Inc is C$8.50, about 53.2% above its February 3 closing price of C$5.55

• The stock recently traded at 75 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release: ID:nCNW8fzvFa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.